Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $638.4 million.

  • Amicus Therapeutics' Total Liabilities rose 504.42% to $638.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $638.4 million, marking a year-over-year increase of 504.42%. This contributed to the annual value of $591.0 million for FY2024, which is 432.54% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Total Liabilities of $638.4 million as of Q3 2025, which was up 504.42% from $611.0 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Total Liabilities high stood at $638.4 million for Q3 2025, and its period low was $559.1 million during Q1 2021.
  • For the 5-year period, Amicus Therapeutics' Total Liabilities averaged around $603.7 million, with its median value being $601.1 million (2022).
  • Per our database at Business Quant, Amicus Therapeutics' Total Liabilities soared by 6827.76% in 2021 and then plummeted by 432.54% in 2024.
  • Amicus Therapeutics' Total Liabilities (Quarter) stood at $597.8 million in 2021, then rose by 0.56% to $601.1 million in 2022, then grew by 2.76% to $617.7 million in 2023, then fell by 4.33% to $591.0 million in 2024, then increased by 8.02% to $638.4 million in 2025.
  • Its last three reported values are $638.4 million in Q3 2025, $611.0 million for Q2 2025, and $596.3 million during Q1 2025.